Clinical trials: Attention Deficit Disorder with Hyperactivity
- Condition Attention Deficit Disorder with Hyperactivity
- Funder type Industry (pharma, biotech, devices)
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
The current study will investigate if QbMobile can be used to improve the accuracy and objective identification of reduced ADHD symptoms in tests scores once treatment has been initiated.
- Trial name
- NCT07217977
- Testing
- observational study
- Where
- 7 sites in United States
- Volunteers
- 175 people
- Sponsor
- Qbtech AB
No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD)
An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations
The purpose of this study is to investigate QbMobile ability to collect and provide accurate and objective data which can be used to facilitate assessment and treatment procedures for ADHD in a clinical setting as well as…
- Conditions
- No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
- Trial name
- NCT07220330
- Testing
- QbMobile
- Where
- 3 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Qbtech AB
ADHD, ADHD - Combined Type
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in children (6-12) with ADHD in a laboratory classroom setting.
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05924594
- Testing
- CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
ADHD
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
- Trial name
- NCT07314333
- Testing
- Centanafadine, Methylphenidate, Lisdexamfetamine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy Volunteers, Drug Users
A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
This single-center study will be a single-dose, randomized, double-blind, placebo- and active-controlled crossover study with a single inpatient treatment visit.
- Trial name
- NCT02144415
- Testing
- EB-1020 400 mg, EB-1020 800 mg, lisdexamfetamine 150 mg
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B).
- Trial name
- NCT04085172
- Testing
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 396 people
- Sponsor
- Shire
Attention Deficit/Hyperactivity Disorder
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD.
- Trial name
- NCT05428033
- Testing
- centanafadine capsule
- Where
- United States
- Volunteers
- 574 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-Deficit/Hyperactivity Disorder
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
- Trial name
- NCT06185985
- Testing
- SPN-812
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Healthy Adult Participants
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult…
- Trial name
- NCT07486895
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD, Attention Deficit Disorder
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
- Trial name
- NCT05200936
- Testing
- MM120
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 53 people
- Sponsor
- Definium Therapeutics US, Inc.
ADHD
tRNS Treatment for ADHD Symptoms
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD.
- Trial name
- NCT06189703
- Testing
- tRNS
- Where
- 5 sites in United States, Israel
- Volunteers
- 146 people
- Sponsor
- Innosphere
ADHD
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol…
- Trial name
- NCT05972044
- Testing
- Solriamfetol 150 mg, Solriamfetol 300 mg
- Where
- 42 sites in United States
- Volunteers
- 516 people
- Sponsor
- Axsome Therapeutics, Inc.
ADHD, Depression Disorders
Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled…
- Conditions
- ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized
- Trial name
- Rx Meds Gaize (NCT07389473)
- Testing
- Prescription Psychotropic Medications
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Gaize
ADHD, Sleep Disturbance
A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications
This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant…
- Conditions
- ADHD, Sleep Disturbance, Brain Fog
- Trial name
- NCT07380412
- Testing
- Stasis Daytime and Nighttime
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Outliers, Inc.
Attention Deficit Hyperactivity Disorder
Healing Minds: Biofeedback and Breathing Practices in Children and Adolescents With ADHD
The objective of this research proposal is to examine the combined effects of an integrative approach including biofeedback and breathing practices (Healing Minds) on severity of Attention Deficit Hyperactivity Disorder (ADHD) in…
- Trial name
- NCT06648252
- Testing
- Healing Minds Biofeedback and Breathing Practices Intervention
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Attention Deficit Disorder With Hyperactivity (ADHD)
Healing Minds II: Biofeedback, Breathing Practices, Nutrition and Exercise Counseling in Children and Adolescents With ADHD
The Pediatric Healing Minds II intervention includes a biofeedback component, breathing practices nutrition and exercise counseling.
- Trial name
- NCT07180602
- Testing
- Heart Math Biofeedback Breathing Practices, Nutrition Counseling combined with Exercise Counseling
- Where
- United States
- Sponsor
- Hoskinson Health and Wellness Clinic
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Attention-Deficit/Hyperactivity Disorder (ADHD)
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
- Trial name
- ADHD (NCT06215144)
- Testing
- NRCT-101SR
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Neurocentria, Inc.
ADHD
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.
- Trial name
- NCT06673368
- Testing
- NRCT-101SR, NRCT-202XR
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Neurocentria, Inc.